- Home
- NLOP vs RGNX Comparison
NLOP vs RGNX Comparison
Compare NLOP & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NLOP
- RGNX
- Stock Information
- Founded
- NLOP N/A
- RGNX 2008
- Country
- NLOP United States
- RGNX United States
- Employees
- NLOP N/A
- RGNX N/A
- Industry
- NLOP
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NLOP
- RGNX Health Care
- Exchange
- NLOP Nasdaq
- RGNX Nasdaq
- Market Cap
- NLOP 474.6M
- RGNX 387.0M
- IPO Year
- NLOP N/A
- RGNX 2015
- Fundamental
- Price
- NLOP $32.70
- RGNX $8.54
- Analyst Decision
- NLOP Strong Buy
- RGNX Strong Buy
- Analyst Count
- NLOP 1
- RGNX 8
- Target Price
- NLOP $46.00
- RGNX $31.75
- AVG Volume (30 Days)
- NLOP 74.8K
- RGNX 1.1M
- Earning Date
- NLOP 01-01-0001
- RGNX 07-31-2025
- Dividend Yield
- NLOP N/A
- RGNX N/A
- EPS Growth
- NLOP N/A
- RGNX N/A
- EPS
- NLOP N/A
- RGNX N/A
- Revenue
- NLOP $127,453,000.00
- RGNX $156,718,000.00
- Revenue This Year
- NLOP N/A
- RGNX $327.08
- Revenue Next Year
- NLOP N/A
- RGNX N/A
- P/E Ratio
- NLOP N/A
- RGNX N/A
- Revenue Growth
- NLOP N/A
- RGNX 80.70
- 52 Week Low
- NLOP $23.38
- RGNX $5.04
- 52 Week High
- NLOP $34.38
- RGNX $15.36
- Technical
- Relative Strength Index (RSI)
- NLOP 61.83
- RGNX 46.38
- Support Level
- NLOP $32.85
- RGNX $7.82
- Resistance Level
- NLOP $33.66
- RGNX $10.64
- Average True Range (ATR)
- NLOP 0.56
- RGNX 0.82
- MACD
- NLOP 0.08
- RGNX -0.19
- Stochastic Oscillator
- NLOP 63.22
- RGNX 25.57
About NLOP Net Lease Office Properties of Beneficial Interest
Net Lease Office Properties is a Maryland real estate investment trust that, together with its consolidated subsidiaries, owns a diversified portfolio of office properties that are primarily leased to corporate tenants on a single-tenant, net-lease basis. Its net leases generally specify a base rent with rent increases and require the tenant to pay substantially all costs associated with operating and maintaining the property. Its portfolio includes approximately 1.2 million square feet of Green-Certified Buildings, 2 LEED-certified buildings, and 1 BREEAM-certified building.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.